New regimens to treat MAC lung disease in people with lung problems or weak immune systems
Official title: Pioneering new regimens to treat Mycobacterium avium complex pulmonary disease
Funded at Johns Hopkins University · NIH-11572320 · Data updated 2026-11-12
A study from Johns Hopkins aims to test new drug combinations to treat MAC lung disease in people with damaged lungs or weakened immune systems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 27, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $703,040 |
| NIH project number | 1R56AI196062-01A1 |
| Project ID | NIH-11572320 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with MAC lung disease or those with underlying lung conditions or weakened immunity who could benefit from improved treatment options.
✕Less likely to help
Patients whose MAC infection does not respond to new regimens or who cannot tolerate the drugs being tested may see limited or no benefit.
What this research studies
This research will use a validated mouse model of MAC lung disease to test combinations of existing antibiotics and new drugs that follow current guidelines for three-drug regimens. It also explores innovative ideas beyond standard therapies, including trying two β-lactam antibiotics together to see if they work better against MAC. A third aim asks whether it might be possible to simplify regimens and still achieve strong treatment effects. The project builds on current knowledge that MAC lung disease is hard to cure and seeks to improve outcomes for patients who struggle with this infection.
Why it matters
Potential benefit: If successful, patients with MAC lung disease could have more effective treatments with fewer failures and better long-term outcomes.
How similar studies have gone: Preliminary data and prior work suggest some regimens can improve microbiological outcomes in MAC; this project tests next-generation combinations.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Lamichhane, Gyanu — Johns Hopkins University
- Study coordinator: Lamichhane, Gyanu
Related research
Other NIH-funded projects on the same topics.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
Positive airway pressure therapy for older veterans with COPD and sleep apnea overlap
A plan to see if using a CPAP/BAP therapy improves sleep, thinking, and quality of life for older veterans who have both COPD and sleep apnea.
-
Understanding how microbes and our bodies shape HIV-related COPD in LMICs
This project looks at how interactions between the human body and microbes may influence COPD in people living with HIV in low- and middle-income countries.
-
Anti-EMAP II antibody as a first-in-class treatment for COPD-related pulmonary hypertension
A first-in-class antibody treatment is being developed to help people with COPD-related pulmonary hypertension by blocking EMAP II, a molecule involved in lung injury and inflammation.
-
Non-coding RNA and COPD: how RNA structure changes with disease
A COPD research project explores how non-coding RNA structures in adults with COPD change due to genetic differences and how this affects gene activity.
-
Patient-reported outcomes in lung disease due to non-tuberculous mycobacteria
This grant funds research to understand how NTM lung disease affects daily life by asking patients about symptoms and well-being during and after treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.